董事介绍

注:董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
John Ornell Director 68 18.34万美元 未持股 2026-01-01
Robert Rosenthal Director 69 16.72万美元 未持股 2026-01-01
Cynthia M. Friend Director 71 10.06万美元 未持股 2026-01-01
Hermann Requardt Director 71 16.22万美元 未持股 2026-01-01
Laura A. Francis Director 59 未披露 未持股 2026-01-01
Bonnie H. Anderson Director 67 未披露 未持股 2026-01-01
Jack J. Phillips -- Director -- 未披露 未持股 2026-01-01
Frank H. Laukien Chairman, President and Chief Executive Officer 66 344.22万美元 未持股 2026-01-01
Richard A. Packer Director 68 17.92万美元 未持股 2026-01-01
William A. Linton Director 78 15.67万美元 未持股 2026-01-01
Adelene Q. Perkins Director 67 未披露 未持股 2026-01-01
Bonnie H. Anderson Director 68 未披露 未持股 2026-01-01

高管介绍

注:高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Gerald N. Herman Executive Vice President and Chief Financial Officer 67 未披露 未持股 2026-01-01
Falko Busse President, Bruker BioSpin Group 58 未披露 未持股 2026-01-01
Frank H. Laukien Chairman, President and Chief Executive Officer 66 344.22万美元 未持股 2026-01-01
Burkhard Prause President and Chief Executive Officer, Bruker Energy & Supercon Technologies, Inc. 59 96.79万美元 未持股 2026-01-01
Mark R. Munch Executive Vice President, President of Bruker NANO Group and Bruker NANO Surfaces Division 64 153.49万美元 未持股 2026-01-01
Juergen Srega President, Bruker CALID Group and Bruker Daltonics Division 71 107.41万美元 未持股 2026-01-01

董事简历

中英对照 |  中文 |  英文
John Ornell

John Ornell,已从Waters Corporation退休,曾在2001-2003年间,担任财务管理副总裁、首席财务官。任职于Waters Corporation期间,他还负责信息技术、投资者关系、TA仪器部门。他于1994年加入Waters ,成为首席财务官之前,担任过运营、财务方面的各种领导职位。2014年,他继续以兼职、过渡的形式服务于该公司。加入该公司之前,他一些跨国公司担任了愈益重要的多个职务,主要涉及经营财务领域。他在Southern New Hampshire University获得工商管理硕士学位。


John Ornell is retired from Waters Corporation, where he served as Vice President, Finance and Administration and Chief Financial Officer from 2001 to 2013. During his time at Waters, he was also responsible for information technology, investor relations and the TA Instruments Division. Mr. Ornell joined Waters in 1994 and served there in a variety of operational and financial leadership roles before assuming the position of Waters' Chief Financial Officer. During 2014 Mr. Ornell continued to serve Waters on a part-time, transitional basis. Prior to joining Waters, Mr. Ornell progressed through a series of roles of increasing responsibility at a number of multinational corporations, primarily in operational finance functions. Mr. Ornell holds a Master of Business Administration degree from Southern New Hampshire University.
John Ornell,已从Waters Corporation退休,曾在2001-2003年间,担任财务管理副总裁、首席财务官。任职于Waters Corporation期间,他还负责信息技术、投资者关系、TA仪器部门。他于1994年加入Waters ,成为首席财务官之前,担任过运营、财务方面的各种领导职位。2014年,他继续以兼职、过渡的形式服务于该公司。加入该公司之前,他一些跨国公司担任了愈益重要的多个职务,主要涉及经营财务领域。他在Southern New Hampshire University获得工商管理硕士学位。
John Ornell is retired from Waters Corporation, where he served as Vice President, Finance and Administration and Chief Financial Officer from 2001 to 2013. During his time at Waters, he was also responsible for information technology, investor relations and the TA Instruments Division. Mr. Ornell joined Waters in 1994 and served there in a variety of operational and financial leadership roles before assuming the position of Waters' Chief Financial Officer. During 2014 Mr. Ornell continued to serve Waters on a part-time, transitional basis. Prior to joining Waters, Mr. Ornell progressed through a series of roles of increasing responsibility at a number of multinational corporations, primarily in operational finance functions. Mr. Ornell holds a Master of Business Administration degree from Southern New Hampshire University.
Robert Rosenthal

Robert Rosenthal,目前担任Taconic Biosciences, Inc.(制药和生物技术行业研究模型私人供应商)的首席执行官(2014年6月加入Taconic Biosciences以来)。他此前曾担任开发诊断、治疗、医疗设备和生命科学工具公司的多种高级管理职务,最近担任IMI Intelligent Medical Implants, AG(一个医疗技术公司)的总裁兼首席执行官(从2010年到2012年)、Magellan Biosciences, Inc.(临床诊断和生命科学研究工具的供应商)的总裁兼首席执行官(从2005年到2009年)。他曾担任Safeguard Scientifics, Inc.(早期和成长期的公司的资本的上市供应商)的董事(2007年以来),在那里他是资本管理委员会主席、审计和薪酬委员会的成员。他目前担任Taconic Biosciences and Galvanic Applied Sciences, Inc.(私人控股的加拿大公司)的董事。职业生涯早期,他曾担任Perkin Elmer Inc.、 Thermo Fisher Scientific, Inc.的高级管理职务。他持有Emory University的博士学位,以及Emory University的硕士学位。


Robert Rosenthal currently serves as Chief Executive Officer of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, a position he has held since joining Taconic Biosciences in June 2014. Dr. Rosenthal also serves as a director of Taconic Biosciences. Dr. Rosenthal previously served since 1995 in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of the Board of Directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph. D. from Emory University and a Master of Science degree from the State University of New York.
Robert Rosenthal,目前担任Taconic Biosciences, Inc.(制药和生物技术行业研究模型私人供应商)的首席执行官(2014年6月加入Taconic Biosciences以来)。他此前曾担任开发诊断、治疗、医疗设备和生命科学工具公司的多种高级管理职务,最近担任IMI Intelligent Medical Implants, AG(一个医疗技术公司)的总裁兼首席执行官(从2010年到2012年)、Magellan Biosciences, Inc.(临床诊断和生命科学研究工具的供应商)的总裁兼首席执行官(从2005年到2009年)。他曾担任Safeguard Scientifics, Inc.(早期和成长期的公司的资本的上市供应商)的董事(2007年以来),在那里他是资本管理委员会主席、审计和薪酬委员会的成员。他目前担任Taconic Biosciences and Galvanic Applied Sciences, Inc.(私人控股的加拿大公司)的董事。职业生涯早期,他曾担任Perkin Elmer Inc.、 Thermo Fisher Scientific, Inc.的高级管理职务。他持有Emory University的博士学位,以及Emory University的硕士学位。
Robert Rosenthal currently serves as Chief Executive Officer of Taconic Biosciences, Inc., a privately-held provider of research models for the pharmaceutical and biotech industry, a position he has held since joining Taconic Biosciences in June 2014. Dr. Rosenthal also serves as a director of Taconic Biosciences. Dr. Rosenthal previously served since 1995 in a variety of senior management positions with companies involved in the development of diagnostics, therapeutics, medical devices, and life sciences tools, most recently including from 2010 through 2012 as President and Chief Executive Officer of IMI Intelligent Medical Implants, AG, a medical technology company, and from 2005 through 2009 as President and Chief Executive Officer of Magellan Biosciences, Inc., a provider of clinical diagnostics and life sciences research tools. Dr. Rosenthal has served since 2007 as a director of Safeguard Scientifics, Inc., a publicly-traded provider of capital for early- and growth-stage companies, and as Chairman of the Board of Directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, Inc., a privately-held Canadian company. Earlier in his career, Dr. Rosenthal served in senior management positions at Perkin Elmer Inc. and Thermo Fisher Scientific, Inc. Dr. Rosenthal holds a Ph. D. from Emory University and a Master of Science degree from the State University of New York.
Cynthia M. Friend

Cynthia M. Friend,目前担任Harvard University的the Rowland Institute(公益组织,旨在支持事业初期科学家的高风险/高回报研究)的主管。2014年,她成为了Sustainable Catalysis at Harvard University的the Energy Frontier Research Center(能源资助的多机构中心,专注于有效催化反应的设计)的主管,负责中心的财政健康管理和战略科学规划。她于1998年成为Harvard University的the Theodore Williams Richards Professor of Chemistry,2002年成为Professor of Materials Science。自1982年进入the Harvard University Department of Chemistry以来,她已经担任过多个高级教职工和领导职位,其中1999年至2012年间担任文理学院院长顾问,2001年至2011年间担任the Harvard Materials Research Science and Engineering Center的助理主任,2004年至2007年间担任the Harvard University Department of Chemistry and Chemical Biology的院长。她因自己的科学和学术研究已经获得了多个奖项,担任过多个研究和科学顾问委员会的成员。她获得了the University of California伯克利分校的化学博士学位。


Cynthia M. Friend,is the president and CEO of the Kavli Foundation and is the Theodore Williams Richards Professor of Chemistry and Professor of Materials Science Emerita at Harvard University. Dr. Friend served in a variety of leadership roles at Harvard, including several advisory roles for the Dean of Faculty of Arts and Sciences and as Chair of the Harvard University Department of Chemistry and Chemical Biology from 2004 to 2007. From 2013 until 2019, Dr. Friend served as Director of the Rowland Institute at Harvard University, a non-profit organization whose goal is to support the high risk/high reward research of early career scientists. In 2014, she became Director of the Energy Frontier Research Center for Sustainable Catalysis at Harvard University, a Department of Energy-funded multi-institution effort focused on the design of efficient catalytic processes, where her responsibilities include management of the fiscal health of the Center and strategic scientific planning. Dr. Friend has received numerous awards for her scientific research and scholarship and has served on a number of research and scientific advisory boards and panels. She is currently the Chair of the Basic Energy Sciences Advisory Committee, a Federal Advisory Committee. Dr. Friend holds a Ph.D. in Chemistry from the University of California, Berkeley.
Cynthia M. Friend,目前担任Harvard University的the Rowland Institute(公益组织,旨在支持事业初期科学家的高风险/高回报研究)的主管。2014年,她成为了Sustainable Catalysis at Harvard University的the Energy Frontier Research Center(能源资助的多机构中心,专注于有效催化反应的设计)的主管,负责中心的财政健康管理和战略科学规划。她于1998年成为Harvard University的the Theodore Williams Richards Professor of Chemistry,2002年成为Professor of Materials Science。自1982年进入the Harvard University Department of Chemistry以来,她已经担任过多个高级教职工和领导职位,其中1999年至2012年间担任文理学院院长顾问,2001年至2011年间担任the Harvard Materials Research Science and Engineering Center的助理主任,2004年至2007年间担任the Harvard University Department of Chemistry and Chemical Biology的院长。她因自己的科学和学术研究已经获得了多个奖项,担任过多个研究和科学顾问委员会的成员。她获得了the University of California伯克利分校的化学博士学位。
Cynthia M. Friend,is the president and CEO of the Kavli Foundation and is the Theodore Williams Richards Professor of Chemistry and Professor of Materials Science Emerita at Harvard University. Dr. Friend served in a variety of leadership roles at Harvard, including several advisory roles for the Dean of Faculty of Arts and Sciences and as Chair of the Harvard University Department of Chemistry and Chemical Biology from 2004 to 2007. From 2013 until 2019, Dr. Friend served as Director of the Rowland Institute at Harvard University, a non-profit organization whose goal is to support the high risk/high reward research of early career scientists. In 2014, she became Director of the Energy Frontier Research Center for Sustainable Catalysis at Harvard University, a Department of Energy-funded multi-institution effort focused on the design of efficient catalytic processes, where her responsibilities include management of the fiscal health of the Center and strategic scientific planning. Dr. Friend has received numerous awards for her scientific research and scholarship and has served on a number of research and scientific advisory boards and panels. She is currently the Chair of the Basic Energy Sciences Advisory Committee, a Federal Advisory Committee. Dr. Friend holds a Ph.D. in Chemistry from the University of California, Berkeley.
Hermann Requardt

Hermann Requardt,目前担任许多欧洲公共和私人生命科学和医疗技术公司的独立战略顾问。2009年至2015年2月,他曾担任Siemens AG的(位于德国慕尼黑)的医疗保健部门的首席执行官。他也曾担任Siemens AG的首席技术官(从2008年到2011年)。2006年至2015年1月,他曾担任Siemens AG的管理委员会的成员,期间也曾担任Siemens公司及其附属公司的多种区域和运营职务。他于1984年加入Siemens Medical Solutions,担任多种职务,并不断被提拔,并于1994年担任磁共振业务单元的全球职务。他是the University of Frankfurt的物理学名誉教授,也任职于一些德国学术和工业委员会,其中包括担任Fraunhofer-Gesellschaft(位于欧洲)的最大的面向应用的研究机构的副主席、Acatech的执行委员会成员,以及the National Academy of Science and Engineering的成员。他是Dekra SE(位于德国斯图加特)的咨询委员会成员,以及Sivantos Group(原为Siemens Audiology Solutions)的监事会成员(2015年Siemens AG拆分出来之前)。他持有the University of Frankfurt的生物物理学博士学位,专注于辐射生物物理和微生物学。


Hermann Requardt currently serves as an independent strategic advisor to a number of European public and private life science and healthcare technology companies. From 2009 to February 2015 he served as Chief Executive Officer of the healthcare division of Munich, Germany-based Siemens AG. He also served as Chief Technology Officer of Siemens AG from 2008 through 2011. Additionally, from 2006 through January 2015 he was a member of the Siemens AG Managing Board, during which time he also held a variety of regional and operational responsibilities at Siemens and its affiliates. Dr. Requardt joined Siemens Medical Solutions in 1984 and served there in roles of increasing responsibility before assuming global responsibility for the magnetic resonance business unit in 1994. Dr. Requardt is an honorary Professor of Physics at the University of Frankfurt and serves on several academic and industrial boards in Germany, including, among other positions, serving as Vice Chairman of Fraunhofer-Gesellschaft, Europe's largest application-oriented research organization, and as a member of the Executive Board of Acatech, the National Academy of Science and Engineering. He also is a member of the Advisory Board of Dekra SE, headquartered in Stuttgart, Germany, and the Supervisory Board of Sivantos Group, which was Siemens Audiology Solutions prior to its spin-off from Siemens AG in early 2015. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt.
Hermann Requardt,目前担任许多欧洲公共和私人生命科学和医疗技术公司的独立战略顾问。2009年至2015年2月,他曾担任Siemens AG的(位于德国慕尼黑)的医疗保健部门的首席执行官。他也曾担任Siemens AG的首席技术官(从2008年到2011年)。2006年至2015年1月,他曾担任Siemens AG的管理委员会的成员,期间也曾担任Siemens公司及其附属公司的多种区域和运营职务。他于1984年加入Siemens Medical Solutions,担任多种职务,并不断被提拔,并于1994年担任磁共振业务单元的全球职务。他是the University of Frankfurt的物理学名誉教授,也任职于一些德国学术和工业委员会,其中包括担任Fraunhofer-Gesellschaft(位于欧洲)的最大的面向应用的研究机构的副主席、Acatech的执行委员会成员,以及the National Academy of Science and Engineering的成员。他是Dekra SE(位于德国斯图加特)的咨询委员会成员,以及Sivantos Group(原为Siemens Audiology Solutions)的监事会成员(2015年Siemens AG拆分出来之前)。他持有the University of Frankfurt的生物物理学博士学位,专注于辐射生物物理和微生物学。
Hermann Requardt currently serves as an independent strategic advisor to a number of European public and private life science and healthcare technology companies. From 2009 to February 2015 he served as Chief Executive Officer of the healthcare division of Munich, Germany-based Siemens AG. He also served as Chief Technology Officer of Siemens AG from 2008 through 2011. Additionally, from 2006 through January 2015 he was a member of the Siemens AG Managing Board, during which time he also held a variety of regional and operational responsibilities at Siemens and its affiliates. Dr. Requardt joined Siemens Medical Solutions in 1984 and served there in roles of increasing responsibility before assuming global responsibility for the magnetic resonance business unit in 1994. Dr. Requardt is an honorary Professor of Physics at the University of Frankfurt and serves on several academic and industrial boards in Germany, including, among other positions, serving as Vice Chairman of Fraunhofer-Gesellschaft, Europe's largest application-oriented research organization, and as a member of the Executive Board of Acatech, the National Academy of Science and Engineering. He also is a member of the Advisory Board of Dekra SE, headquartered in Stuttgart, Germany, and the Supervisory Board of Sivantos Group, which was Siemens Audiology Solutions prior to its spin-off from Siemens AG in early 2015. Dr. Requardt holds a Ph.D. in Biophysics, with a focus on radiation biophysics and microbiology, from the University of Frankfurt.
Laura A. Francis

LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前,Francis女士于2012年12月至2014年9月担任Auxogyn,Inc.(一家女性健康公司)的首席财务官。2004年9月至2012年12月,Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月,Francis女士担任Bruker Biosciences Corporation(一家公共生命科学仪器公司)的首席财务官。2001年5月至2002年3月,Francis女士担任Nutra-Park Inc.(一家农业生物技术公司)的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm,Inc.(一家软件公司)首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company(一家咨询公司)业务经理。在她的职业生涯早期,Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学(University of Wisconsin)获得工商管理学士学位,在斯坦福大学(Stanford University)获得工商管理硕士学位。她是加州不活跃的注册会计师。


Laura A. Francis has served as Chief Financial Officer since May 2015. Prior to joining, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women's health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California.
LauraA.Francis自2015年5月起担任我们的首席财务官。在加入我们之前,Francis女士于2012年12月至2014年9月担任Auxogyn,Inc.(一家女性健康公司)的首席财务官。2004年9月至2012年12月,Francis女士担任生命科学试剂公司Promega Corporation的财务Vice President、首席财务官和财务主管。2002年3月至2004年9月,Francis女士担任Bruker Biosciences Corporation(一家公共生命科学仪器公司)的首席财务官。2001年5月至2002年3月,Francis女士担任Nutra-Park Inc.(一家农业生物技术公司)的首席运营官和首席财务官。Francis从1999年4月到2001年5月担任Hypercosm,Inc.(一家软件公司)首席财务官。Francis从1995年10月到1999年4月担任McKinsey&Company(一家咨询公司)业务经理。在她的职业生涯早期,Francis女士是会计师事务所Coopers&Lybrand的审计经理。Francis女士在威斯康星大学(University of Wisconsin)获得工商管理学士学位,在斯坦福大学(Stanford University)获得工商管理硕士学位。她是加州不活跃的注册会计师。
Laura A. Francis has served as Chief Financial Officer since May 2015. Prior to joining, Ms. Francis was the Chief Financial Officer for Auxogyn, Inc., a women's health company, from December 2012 to September 2014. From September 2004 to December 2012 Ms. Francis served as Vice President of Finance, Chief Financial Officer and Treasurer for Promega Corporation, a life science reagent company. From March 2002 to September 2004 Ms. Francis served as the Chief Financial Officer of Bruker BioSciences Corporation, a public life science instrumentation company. From May 2001 to March 2002 Ms. Francis served as Chief Operating Officer and Chief Financial Officer of Nutra-Park Inc., an agricultural biotechnology company. From April 1999 to May 2001 Ms. Francis was Chief Financial Officer of Hypercosm, Inc., a software company. From October 1995 to April 1999 Ms. Francis was an engagement manager with McKinsey & Company, a consulting firm. Early in her career, Ms. Francis was an audit manager with Coopers & Lybrand, an accounting firm. Ms. Francis received a B.B.A. from the University of Wisconsin and an M.B.A. from Stanford University. She is a Certified Public Accountant inactive in the State of California.
Bonnie H. Anderson

Bonnie H. Anderson,是PinkDx,Inc.的首席执行官兼董事长,该公司是一家女性医疗保健公司,她于2022年创立。Anderson女士于2008年与他人共同创立了Veracyte,自2008年2月起担任Veracyte的董事会成员,包括2016年至2023年担任董事会主席。2008年2月至2021年5月,Anderson女士担任Veracyte的首席执行官。2013年8月至2017年2月,Anderson女士担任Veracyte总裁。安德森女士此前曾于2006年至2008年担任独立战略顾问。从2000年9月到2006年3月,Anderson女士在Beckman Coulter, Inc.担任副总裁,该公司是一家公开上市的生物医学测试仪器系统、测试和用品制造商。安德森女士目前担任私营生物技术公司DNA Script的董事会成员,并担任21世纪医学联盟主席和凯克应用生命科学研究所董事会成员。安德森女士拥有医学技术理学学士学位和宾夕法尼亚印第安纳大学荣誉理学博士学位。


Bonnie H. Anderson,is the CEO and Chairman of PinkDx, Inc., a women's healthcare company, she founded in 2022. Ms. Anderson co-founded Veracyte in 2008 and served as a member of the Board of Directors of Veracyte since February 2008, including service as chair of the Board of Directors from 2016 to 2023. From February 2008 to May 2021, Ms. Anderson served as Veracyte's CEO. From August 2013 to February 2017, Ms. Anderson served as President at Veracyte. Ms. Anderson previously acted as an independent strategic consultant from 2006 to 2008. From September 2000 to March 2006, Ms. Anderson served as a Vice President at Beckman Coulter, Inc., a publicly traded manufacturer of biomedical testing instrument systems, tests and supplies. Ms. Anderson currently serves on the Board of Directors of DNA Script, a private biotechnology company, and serves as President of the Coalition for 21st Century Medicine and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a Bachelor of Science degree in Medical Technology and an honorary Doctorate of Science degree from Indiana University of Pennsylvania.
Bonnie H. Anderson,是PinkDx,Inc.的首席执行官兼董事长,该公司是一家女性医疗保健公司,她于2022年创立。Anderson女士于2008年与他人共同创立了Veracyte,自2008年2月起担任Veracyte的董事会成员,包括2016年至2023年担任董事会主席。2008年2月至2021年5月,Anderson女士担任Veracyte的首席执行官。2013年8月至2017年2月,Anderson女士担任Veracyte总裁。安德森女士此前曾于2006年至2008年担任独立战略顾问。从2000年9月到2006年3月,Anderson女士在Beckman Coulter, Inc.担任副总裁,该公司是一家公开上市的生物医学测试仪器系统、测试和用品制造商。安德森女士目前担任私营生物技术公司DNA Script的董事会成员,并担任21世纪医学联盟主席和凯克应用生命科学研究所董事会成员。安德森女士拥有医学技术理学学士学位和宾夕法尼亚印第安纳大学荣誉理学博士学位。
Bonnie H. Anderson,is the CEO and Chairman of PinkDx, Inc., a women's healthcare company, she founded in 2022. Ms. Anderson co-founded Veracyte in 2008 and served as a member of the Board of Directors of Veracyte since February 2008, including service as chair of the Board of Directors from 2016 to 2023. From February 2008 to May 2021, Ms. Anderson served as Veracyte's CEO. From August 2013 to February 2017, Ms. Anderson served as President at Veracyte. Ms. Anderson previously acted as an independent strategic consultant from 2006 to 2008. From September 2000 to March 2006, Ms. Anderson served as a Vice President at Beckman Coulter, Inc., a publicly traded manufacturer of biomedical testing instrument systems, tests and supplies. Ms. Anderson currently serves on the Board of Directors of DNA Script, a private biotechnology company, and serves as President of the Coalition for 21st Century Medicine and on the Board of Trustees of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a Bachelor of Science degree in Medical Technology and an honorary Doctorate of Science degree from Indiana University of Pennsylvania.
Jack J. Phillips
暂无中文简介

暂无英文简介
暂无中文简介
暂无英文简介
Frank H. Laukien

Frank H. Laukien,自1991年2月起,担任本公司的董事长、总裁兼首席执行官;现任布鲁克公司的最大股东。他还担任本公司多间附属公司的董事。自2002年8月至2003年7月布鲁克道尔顿公司和布鲁克AXS公司合并,他担任前上市公司布鲁克AXS公司及其前身公司的执行董事长。此外,从1997年10月至2002年8月,出任董事会主席;从1997年10月至2000年3月,担任布鲁克AXS公司的首席执行官。直至2010年2月,他担任布鲁克BIOSPIN集团的联席首席执行官。弗兰克博士是Joerg C. Laukien(本公司的董事兼布鲁克BIOSPIN公司的执行董事长)的兄弟。弗兰克博士担任生命科学和诊断协会ALDA分析部董事,一个在过去十年被称为分析与生命科学系统协会的行业组织;并从2002年到2003年,担任ALDA董事长。弗兰克博士持有麻省理工学院的学士学位和哈佛大学的化学物理博士学位。 他是MIT科学学院的院长顾问委员会的成员;从2006年到2013年中,担任河流州学校(位于美国马萨诸塞州韦斯顿)的受托人。作为本公司最大的股东,以及他长期领导公司成长的经验,他给董事会带来了具有对公司运营各方面深入了解的一位重要股东的观点。他还提供了在组织管理、战略规划、全球金融和业务发展的丰富行政经验,以及充分理解本公司的关键技术和行业动态的科学技术背景。弗兰克博士现任该公司的最好特别委员会。


Frank H. Laukien,serves as a director of various subsidiaries of Bruker, none of which are publicly traded companies. Dr. Laukien has been elected as a governing trustee of the Dana-Farber Cancer Institute in 2023, and he has been reelected to the ALDA (Analytical, Life-Science & Diagnostics Association) Board in 2021. Dr. Laukien holds a Bachelor of Science degree in physics from MIT, as well as a Ph.D. in chemical physics from Harvard. Dr. Laukien currently serves on the MIT Chemistry Visiting Committee. In 2021, he has been appointed to the Scientific Advisory Boards of the Australian National Phenome Center, and of the Berlin-Brandenburg Innovation Cluster for Cell-based Medicine 'Virchow 2.0'. He is a non-voting board observer in Terrain Biosciences, Inc., an RNA CRO/CDMO startup in which Bruker has a minority investment. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. In 2021, Dr. Laukien was appointed as a Visiting Scholar at Harvard University in the Department of Chemistry and Chemical Biology, and this appointment has been extended for 2024. At Harvard, he participates in the Harvard Origins of Life Initiative and is a co-founder of the Galileo Project at the Center for Astrophysics. In 2021-2023, Dr. Laukien was co-chair of the new scientific working group 'Cancer Evolution' by the American Association of Cancer Research (AACR) Dr. Laukien also is a founding shareholder, angel investor and board member of two New England start-up companies in therapeutics and in space exploration, both outside of Bruker's strategic scope. Dr. Laukien is the author of two scholarly books, called 'Active Biological Evolution' (2022), and 'Origins & Evolution' (2024). Additionally, Dr. Laukien sits on the Boards of Directors of three non-profit entities: FREOPP, a non-partisan think tank that explores ways to expand economic opportunities to disadvantaged people; Heterodox Academy, which promotes viewpoint diversity in Higher Education; and the MIT Free Speech Alliance.
Frank H. Laukien,自1991年2月起,担任本公司的董事长、总裁兼首席执行官;现任布鲁克公司的最大股东。他还担任本公司多间附属公司的董事。自2002年8月至2003年7月布鲁克道尔顿公司和布鲁克AXS公司合并,他担任前上市公司布鲁克AXS公司及其前身公司的执行董事长。此外,从1997年10月至2002年8月,出任董事会主席;从1997年10月至2000年3月,担任布鲁克AXS公司的首席执行官。直至2010年2月,他担任布鲁克BIOSPIN集团的联席首席执行官。弗兰克博士是Joerg C. Laukien(本公司的董事兼布鲁克BIOSPIN公司的执行董事长)的兄弟。弗兰克博士担任生命科学和诊断协会ALDA分析部董事,一个在过去十年被称为分析与生命科学系统协会的行业组织;并从2002年到2003年,担任ALDA董事长。弗兰克博士持有麻省理工学院的学士学位和哈佛大学的化学物理博士学位。 他是MIT科学学院的院长顾问委员会的成员;从2006年到2013年中,担任河流州学校(位于美国马萨诸塞州韦斯顿)的受托人。作为本公司最大的股东,以及他长期领导公司成长的经验,他给董事会带来了具有对公司运营各方面深入了解的一位重要股东的观点。他还提供了在组织管理、战略规划、全球金融和业务发展的丰富行政经验,以及充分理解本公司的关键技术和行业动态的科学技术背景。弗兰克博士现任该公司的最好特别委员会。
Frank H. Laukien,serves as a director of various subsidiaries of Bruker, none of which are publicly traded companies. Dr. Laukien has been elected as a governing trustee of the Dana-Farber Cancer Institute in 2023, and he has been reelected to the ALDA (Analytical, Life-Science & Diagnostics Association) Board in 2021. Dr. Laukien holds a Bachelor of Science degree in physics from MIT, as well as a Ph.D. in chemical physics from Harvard. Dr. Laukien currently serves on the MIT Chemistry Visiting Committee. In 2021, he has been appointed to the Scientific Advisory Boards of the Australian National Phenome Center, and of the Berlin-Brandenburg Innovation Cluster for Cell-based Medicine 'Virchow 2.0'. He is a non-voting board observer in Terrain Biosciences, Inc., an RNA CRO/CDMO startup in which Bruker has a minority investment. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. In 2021, Dr. Laukien was appointed as a Visiting Scholar at Harvard University in the Department of Chemistry and Chemical Biology, and this appointment has been extended for 2024. At Harvard, he participates in the Harvard Origins of Life Initiative and is a co-founder of the Galileo Project at the Center for Astrophysics. In 2021-2023, Dr. Laukien was co-chair of the new scientific working group 'Cancer Evolution' by the American Association of Cancer Research (AACR) Dr. Laukien also is a founding shareholder, angel investor and board member of two New England start-up companies in therapeutics and in space exploration, both outside of Bruker's strategic scope. Dr. Laukien is the author of two scholarly books, called 'Active Biological Evolution' (2022), and 'Origins & Evolution' (2024). Additionally, Dr. Laukien sits on the Boards of Directors of three non-profit entities: FREOPP, a non-partisan think tank that explores ways to expand economic opportunities to disadvantaged people; Heterodox Academy, which promotes viewpoint diversity in Higher Education; and the MIT Free Speech Alliance.
Richard A. Packer

Richard A. Packer,自1999年11月起,担任卓尔医学产品公司的首席执行官兼董事,一家提供复苏设备和相关软件解决方案的上市公司(2012年4月被日本旭化成公司收购)。从1999年至2010年11月,他曾担任卓尔医学产品公司的董事长。从1996年直到1999年被任命为董事长兼首席执行官,他一直担任卓尔医学产品公司的总裁、首席运营官兼董事。从1992年到1996年,他曾担任卓尔医学产品公司的运营副总裁;1995年至1996年,担任卓尔医学产品公司北美销售部首席财务官兼负责人。在加盟卓尔医学产品公司之前,他在惠斯勒公司担任各部门副总裁长达五年,一家消费电子公司。在1987年加入惠斯勒公司之前,他担任咨询公司PRTM/KPMG的经理,专业从事高科技公司运营。 他是MassMEDIC的前任主席,一家马萨诸塞州的医疗器械行业协会。目前,他担任医疗器械制造商协会和卓尔医学产品公司基金会的董事会成员。他持有哈佛商学院的工商管理硕士学位和度伦斯勒理工学院的理学士和工程硕士学位。帕克先生在医疗器械行业拥有丰富的财务、运营和管理经验。他给董事会甙类在公司治理、上市公司的战略规划和赔偿事宜方面的显著经验。他现任职于本公司的审核委员会,并且是提名委员会的主席。


Richard A. Packer,is a Vice Presidential Executive Officer of Asahi Kasei Corporation, which is traded on the Tokyo exchange, and operates in the fields of materials and chemicals, housing and construction materials, and healthcare. In this role he leads a number of corporate initiatives to improve the operations of Asahi Kasei's global businesses. Mr. Packer was formerly the leader of Asahi Kasei's healthcare business unit, with revenues over $4 billion operating in the fields of medical equipment and devices, pharmaceuticals and biotechnology, and bioprocess related equipment, supplies and services. Previously, Mr. Packer served as the non-executive Chairman of ZOLL Medical Corporation, a company that was publicly traded until it was acquired by Asahi Kasei Corporation in April 2012. From November 1999 to April 2016, Mr. Packer was the Chief Executive Officer and a director of ZOLL. He served as Chairman of ZOLL from 1999 until November 2010. From 1992 until his appointment as Chairman and Chief Executive Officer in 1999, Mr. Packer served in a number of roles, including Chief Operating Officer, Chief Financial Officer, Head of North American Sales, and Vice President of Operations. Prior to joining ZOLL, Mr. Packer served as Vice President of various functions for Whistler Corporation, a consumer electronics company. Previously, Mr. Packer was a manager with the consulting firm of PRTM/KPMG, specializing in the operations of high technology companies. Mr. Packer is the past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He also currently serves as a board member of the Medical Device Manufacturers Association and the ZOLL Foundation. He has served as a member of the Board of Directors of numerous public and private companies. Mr. Packer holds a Master of Business Administration from the Harvard Business School, as well as Bachelor of Science and Master of Engineering degrees from Rensselaer Polytechnic Institute. Mr. Packer has extensive financial, operations and management experience in the medical devices industry.
Richard A. Packer,自1999年11月起,担任卓尔医学产品公司的首席执行官兼董事,一家提供复苏设备和相关软件解决方案的上市公司(2012年4月被日本旭化成公司收购)。从1999年至2010年11月,他曾担任卓尔医学产品公司的董事长。从1996年直到1999年被任命为董事长兼首席执行官,他一直担任卓尔医学产品公司的总裁、首席运营官兼董事。从1992年到1996年,他曾担任卓尔医学产品公司的运营副总裁;1995年至1996年,担任卓尔医学产品公司北美销售部首席财务官兼负责人。在加盟卓尔医学产品公司之前,他在惠斯勒公司担任各部门副总裁长达五年,一家消费电子公司。在1987年加入惠斯勒公司之前,他担任咨询公司PRTM/KPMG的经理,专业从事高科技公司运营。 他是MassMEDIC的前任主席,一家马萨诸塞州的医疗器械行业协会。目前,他担任医疗器械制造商协会和卓尔医学产品公司基金会的董事会成员。他持有哈佛商学院的工商管理硕士学位和度伦斯勒理工学院的理学士和工程硕士学位。帕克先生在医疗器械行业拥有丰富的财务、运营和管理经验。他给董事会甙类在公司治理、上市公司的战略规划和赔偿事宜方面的显著经验。他现任职于本公司的审核委员会,并且是提名委员会的主席。
Richard A. Packer,is a Vice Presidential Executive Officer of Asahi Kasei Corporation, which is traded on the Tokyo exchange, and operates in the fields of materials and chemicals, housing and construction materials, and healthcare. In this role he leads a number of corporate initiatives to improve the operations of Asahi Kasei's global businesses. Mr. Packer was formerly the leader of Asahi Kasei's healthcare business unit, with revenues over $4 billion operating in the fields of medical equipment and devices, pharmaceuticals and biotechnology, and bioprocess related equipment, supplies and services. Previously, Mr. Packer served as the non-executive Chairman of ZOLL Medical Corporation, a company that was publicly traded until it was acquired by Asahi Kasei Corporation in April 2012. From November 1999 to April 2016, Mr. Packer was the Chief Executive Officer and a director of ZOLL. He served as Chairman of ZOLL from 1999 until November 2010. From 1992 until his appointment as Chairman and Chief Executive Officer in 1999, Mr. Packer served in a number of roles, including Chief Operating Officer, Chief Financial Officer, Head of North American Sales, and Vice President of Operations. Prior to joining ZOLL, Mr. Packer served as Vice President of various functions for Whistler Corporation, a consumer electronics company. Previously, Mr. Packer was a manager with the consulting firm of PRTM/KPMG, specializing in the operations of high technology companies. Mr. Packer is the past Chairperson of MassMEDIC, the industry council for Medical Devices in Massachusetts. He also currently serves as a board member of the Medical Device Manufacturers Association and the ZOLL Foundation. He has served as a member of the Board of Directors of numerous public and private companies. Mr. Packer holds a Master of Business Administration from the Harvard Business School, as well as Bachelor of Science and Master of Engineering degrees from Rensselaer Polytechnic Institute. Mr. Packer has extensive financial, operations and management experience in the medical devices industry.
William A. Linton

William A. Linton,现任本公司董事会的首席董事。2004年3月,他被董事会独立成员任命为首席董事。作为首席董事,林顿博士执行一个首席董事的通常职责,包括担任管理层和董事会之间的联络。自1978年以来,林顿博士一直担任Promega公司的董事长、总裁兼首席执行官,一家由林顿博士创立的位于威斯康星州麦迪逊的私人持有的生命科学供应公司。林顿博士持有加州大学伯克利分校的学士学位(1970年)和韩国韩南大学的名誉博士学位(2004年)。自2001年以来,林顿博士担任威斯康辛州技术委员会的董事;还担任ALDA(分析、生命科学和诊断协会)的董事,一个前身为分析和生命科学系统协会的行业组织;担任海弗特研究协会的董事,一个非营利性的医疗研究机构;并且是生物制药技术中心研究所所长。


William A. Linton,has served as the Chairman, President and Chief Executive Officer of Promega Corporation in Madison, Wisconsin, a privately held life science supply company founded by Dr. Linton. Dr. Linton received a Bachelor of Science degree from University of California, Berkeley in 1970 and honorary doctorate degrees from Hannam University (Korea) in 2004 and the University of Wisconsin Madison in 2015. Dr. Linton is a director of ALDA, a director of Heffter Research Institute (a non-profit research institute), a member of the Supervisory Board of Eppendorf AG, Hamburg (a private life sciences company), founder and Executive Director of Usona Institute (a non-profit medical research organization) and President of the BioPharmaceutical Technology Center Institute (a non- profit organization).
William A. Linton,现任本公司董事会的首席董事。2004年3月,他被董事会独立成员任命为首席董事。作为首席董事,林顿博士执行一个首席董事的通常职责,包括担任管理层和董事会之间的联络。自1978年以来,林顿博士一直担任Promega公司的董事长、总裁兼首席执行官,一家由林顿博士创立的位于威斯康星州麦迪逊的私人持有的生命科学供应公司。林顿博士持有加州大学伯克利分校的学士学位(1970年)和韩国韩南大学的名誉博士学位(2004年)。自2001年以来,林顿博士担任威斯康辛州技术委员会的董事;还担任ALDA(分析、生命科学和诊断协会)的董事,一个前身为分析和生命科学系统协会的行业组织;担任海弗特研究协会的董事,一个非营利性的医疗研究机构;并且是生物制药技术中心研究所所长。
William A. Linton,has served as the Chairman, President and Chief Executive Officer of Promega Corporation in Madison, Wisconsin, a privately held life science supply company founded by Dr. Linton. Dr. Linton received a Bachelor of Science degree from University of California, Berkeley in 1970 and honorary doctorate degrees from Hannam University (Korea) in 2004 and the University of Wisconsin Madison in 2015. Dr. Linton is a director of ALDA, a director of Heffter Research Institute (a non-profit research institute), a member of the Supervisory Board of Eppendorf AG, Hamburg (a private life sciences company), founder and Executive Director of Usona Institute (a non-profit medical research organization) and President of the BioPharmaceutical Technology Center Institute (a non- profit organization).
Adelene Q. Perkins

Adelene Q. Perkins自2010年1月起担任首席执行官。她曾于2008年10月至2017年1月期间担任总裁,2008年10月至2009年12月期间担任首席商务官,并于2006年9月至2008年10月期间担任执行副总裁兼首席商务官。Perkins女士从2006年2月起担任IPI执行副总裁,直到2006年9月该公司与DPI合并;从2002年6月起担任IPI首席商务官,直到DPI合并。在加入IPI之前,Perkins女士于2000年至2002年期间担任私营制药公司TransForm Pharmaceuticals,Inc.的业务和企业发展副总裁。从1992年到1999年,Perkins女士在Genetics Institute担任过多个职位,最近担任新兴业务副总裁和DiscoverEase业务部门总经理。Perkins女士自2012年起担任生物技术行业组织的董事会成员;自2017年起担任分析仪器的上市制造商Bruker Corporation;自2017年起担任麻省总医院;自2014年起担任非营利组织马萨诸塞州生物技术委员会;自2013年起担任非营利性社会服务公司Project Hope。帕金斯女士在2015年至2016年期间担任私营生物技术公司Padlock Therapeutics的董事会成员,并在2014年至2016年期间担任马萨诸塞州生命科学中心的财务主管。从1985年到1992年,珀金斯女士在战略咨询公司贝恩公司担任过多个职位。Perkins女士获得维拉诺瓦大学化学工程学士学位和哈佛商学院工商管理硕士学位。


Adelene Q. Perkins has served as Chief Executive Officer since January 2010. She previously served as President between October 2008 and January 2017 Chief Business Officer from October 2008 through December 2009 and Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999 Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served on the board of directors for the Biotechnology Industry Organization since 2012; the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2017; Massachusetts General Hospital since 2017; the Massachusetts Biotechnology Council, a not-for-profit organization, since 2014; and Project Hope, a not-for-profit social services company, since 2013. Ms. Perkins was on the board of Padlock Therapeutics, a privately held biotechnology company, from 2015 to 2016 and was treasurer of the Massachusetts Life Sciences Center from 2014 to 2016. From 1985 to 1992 Ms. Perkins held a variety of positions at Bain & Company, a strategy consulting firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.
Adelene Q. Perkins自2010年1月起担任首席执行官。她曾于2008年10月至2017年1月期间担任总裁,2008年10月至2009年12月期间担任首席商务官,并于2006年9月至2008年10月期间担任执行副总裁兼首席商务官。Perkins女士从2006年2月起担任IPI执行副总裁,直到2006年9月该公司与DPI合并;从2002年6月起担任IPI首席商务官,直到DPI合并。在加入IPI之前,Perkins女士于2000年至2002年期间担任私营制药公司TransForm Pharmaceuticals,Inc.的业务和企业发展副总裁。从1992年到1999年,Perkins女士在Genetics Institute担任过多个职位,最近担任新兴业务副总裁和DiscoverEase业务部门总经理。Perkins女士自2012年起担任生物技术行业组织的董事会成员;自2017年起担任分析仪器的上市制造商Bruker Corporation;自2017年起担任麻省总医院;自2014年起担任非营利组织马萨诸塞州生物技术委员会;自2013年起担任非营利性社会服务公司Project Hope。帕金斯女士在2015年至2016年期间担任私营生物技术公司Padlock Therapeutics的董事会成员,并在2014年至2016年期间担任马萨诸塞州生命科学中心的财务主管。从1985年到1992年,珀金斯女士在战略咨询公司贝恩公司担任过多个职位。Perkins女士获得维拉诺瓦大学化学工程学士学位和哈佛商学院工商管理硕士学位。
Adelene Q. Perkins has served as Chief Executive Officer since January 2010. She previously served as President between October 2008 and January 2017 Chief Business Officer from October 2008 through December 2009 and Executive Vice President and Chief Business Officer between September 2006 and October 2008. Ms. Perkins served as Executive Vice President of IPI from February 2006 until its merger with DPI in September 2006 and Chief Business Officer of IPI from June 2002 until the DPI merger. Prior to joining IPI, Ms. Perkins served as Vice President of Business and Corporate Development of TransForm Pharmaceuticals, Inc., a private pharmaceutical company, from 2000 to 2002. From 1992 to 1999 Ms. Perkins held various positions at Genetics Institute, most recently serving as Vice President of Emerging Business and General Manager of the DiscoverEase business unit. Ms. Perkins has served on the board of directors for the Biotechnology Industry Organization since 2012; the Bruker Corporation, a publicly traded manufacturer of analytic instruments, since 2017; Massachusetts General Hospital since 2017; the Massachusetts Biotechnology Council, a not-for-profit organization, since 2014; and Project Hope, a not-for-profit social services company, since 2013. Ms. Perkins was on the board of Padlock Therapeutics, a privately held biotechnology company, from 2015 to 2016 and was treasurer of the Massachusetts Life Sciences Center from 2014 to 2016. From 1985 to 1992 Ms. Perkins held a variety of positions at Bain & Company, a strategy consulting firm. Ms. Perkins received a B.S. in Chemical Engineering from Villanova University and an M.B.A. from Harvard Business School.
Bonnie H. Anderson

Bonnie H. Anderson,自2008年2月起担任联合创始人、首席执行官和董事会成员,自2016年12月起担任董事会主席。2013年8月至2017年2月,她还担任总裁。Anderson在2006年4月至2008年1月期间担任独立战略顾问,包括在2007年7月至2008年1月期间担任战略顾问。Anderson女士于2000年9月至2006年3月在生物医学测试仪器系统、测试和用品制造商Beckman Coulter, Inc.担任副总裁。Anderson女士目前担任Castle Biosciences公司的董事会成员以及凯克应用生命科学研究所的名誉受托人。Anderson女士拥有宾夕法尼亚印第安纳大学医学技术学士学位。


Bonnie H. Anderson has served as co-founder, Chief Executive Officer and as a member of board of directors since February 2008 and as the Chairman of board of directors since December 2016. From August 2013 to February 2017 she also served as President.Ms. Anderson was an independent strategic consultant from April 2006 to January 2008 including as a strategic consultant from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.
Bonnie H. Anderson,自2008年2月起担任联合创始人、首席执行官和董事会成员,自2016年12月起担任董事会主席。2013年8月至2017年2月,她还担任总裁。Anderson在2006年4月至2008年1月期间担任独立战略顾问,包括在2007年7月至2008年1月期间担任战略顾问。Anderson女士于2000年9月至2006年3月在生物医学测试仪器系统、测试和用品制造商Beckman Coulter, Inc.担任副总裁。Anderson女士目前担任Castle Biosciences公司的董事会成员以及凯克应用生命科学研究所的名誉受托人。Anderson女士拥有宾夕法尼亚印第安纳大学医学技术学士学位。
Bonnie H. Anderson has served as co-founder, Chief Executive Officer and as a member of board of directors since February 2008 and as the Chairman of board of directors since December 2016. From August 2013 to February 2017 she also served as President.Ms. Anderson was an independent strategic consultant from April 2006 to January 2008 including as a strategic consultant from July 2007 to January 2008. Ms. Anderson was a Vice President at Beckman Coulter, Inc., a manufacturer of biomedical testing instrument systems, tests and supplies, from September 2000 to March 2006. Ms. Anderson currently serves as a member of the board of directors of Castle Biosciences, Inc. and as a trustee emeritus of the Keck Graduate Institute of Applied Life Sciences. Ms. Anderson holds a B.S. in Medical Technology from Indiana University of Pennsylvania.

高管简历

中英对照 |  中文 |  英文
Gerald N. Herman

Gerald N. Herman,2016年加入布鲁克,担任副总裁兼公司财务总监。在加入布鲁克之前,Herman先生曾在多家上市公司担任高级管理职务,包括2014年至2016年2月担任公司副总裁— PAREXEL International的临床运营,以及2008年至2013年担任PAREXEL的公司副总裁兼财务总监。在2008年之前,Herman先生是副总裁—— 普雷斯特克的公司控制人。他还曾在多个组织担任财务、咨询和会计职务,包括1979年至1987年在Arthur Andersen LLP担任高级经理。Herman先生是注册会计师(CPA),拥有芝加哥大学工商管理硕士学位和本特利大学税务理学硕士学位。


Gerald N. Herman,oined Bruker in 2016 as Vice President and Corporate Controller. Prior to joining Bruker, Mr. Herman had served in senior executive positions with various publicly-traded companies, including as Corporate Vice President—Clinical Operations of PAREXEL International from 2014 to February 2016, and as Corporate Vice President & Controller-Finance of PAREXEL from 2008 to 2013. Prior to 2008, Mr. Herman was Vice President—Corporate Controller of Presstek, Inc. He also served in financial, consulting and accounting roles at various organizations, including as Senior Manager at Arthur Andersen LLP from 1979 to 1987. Mr. Herman is a Certified Public Accountant (CPA) and holds a Master of Business Administration degree from the University of Chicago, and a Master of Science in Taxation from Bentley University.
Gerald N. Herman,2016年加入布鲁克,担任副总裁兼公司财务总监。在加入布鲁克之前,Herman先生曾在多家上市公司担任高级管理职务,包括2014年至2016年2月担任公司副总裁— PAREXEL International的临床运营,以及2008年至2013年担任PAREXEL的公司副总裁兼财务总监。在2008年之前,Herman先生是副总裁—— 普雷斯特克的公司控制人。他还曾在多个组织担任财务、咨询和会计职务,包括1979年至1987年在Arthur Andersen LLP担任高级经理。Herman先生是注册会计师(CPA),拥有芝加哥大学工商管理硕士学位和本特利大学税务理学硕士学位。
Gerald N. Herman,oined Bruker in 2016 as Vice President and Corporate Controller. Prior to joining Bruker, Mr. Herman had served in senior executive positions with various publicly-traded companies, including as Corporate Vice President—Clinical Operations of PAREXEL International from 2014 to February 2016, and as Corporate Vice President & Controller-Finance of PAREXEL from 2008 to 2013. Prior to 2008, Mr. Herman was Vice President—Corporate Controller of Presstek, Inc. He also served in financial, consulting and accounting roles at various organizations, including as Senior Manager at Arthur Andersen LLP from 1979 to 1987. Mr. Herman is a Certified Public Accountant (CPA) and holds a Master of Business Administration degree from the University of Chicago, and a Master of Science in Taxation from Bentley University.
Falko Busse

Falko Busse,自2018年5月起担任布鲁克 BioSpin集团总裁,负责管理其全球业务。Busse博士自2017年10月起担任布鲁克 BioSpin集团副总裁,直至被任命为总裁。2017年3月至2017年9月,Busse博士在布鲁克 BioSpin集团担任研发、运营和市场营销执行副总裁。Busse博士于2015年6月加入布鲁克 BioSpin集团,并担任研发执行副总裁至2017年2月。在加入布鲁克 BioSpin集团之前,Busse博士于1994年8月至2015年5月期间在飞利浦医疗保健及其子公司担任过各种管理职务,包括2014年1月至2015年5月担任放射解决方案总经理,并于2009年8月至2013年12月担任MR-Therapy总经理。Busse博士拥有Rheinische Friedrich-Wilhelms-Universit t Bonn物理学学士和博士学位。


Falko Busse,has served as President of the Bruker BioSpin Group since May 2018, with responsibility for management of its global operations. Dr. Busse served as Deputy President of the Bruker BioSpin Group from October 2017 until his appointment as President. From March 2017 to September 2017, Dr. Busse served as Executive Vice President of Research and Development, Operations and Marketing at the Bruker BioSpin Group. Dr. Busse joined the Bruker BioSpin Group in June 2015 and served as Executive Vice President of Research and Development until February 2017. Prior to joining the Bruker BioSpin Group, Dr. Busse served in various managerial roles at Philips Healthcare and its subsidiaries from August 1994 until May 2015, including as General Manager Radiology Solutions, from January 2014 to May 2015, and as General Manager MR-Therapy, from August 2009 to December 2013. Dr. Busse holds a B.A. and a Ph.D. in Physics from Rheinische Friedrich-Wilhelms-Universitt Bonn.
Falko Busse,自2018年5月起担任布鲁克 BioSpin集团总裁,负责管理其全球业务。Busse博士自2017年10月起担任布鲁克 BioSpin集团副总裁,直至被任命为总裁。2017年3月至2017年9月,Busse博士在布鲁克 BioSpin集团担任研发、运营和市场营销执行副总裁。Busse博士于2015年6月加入布鲁克 BioSpin集团,并担任研发执行副总裁至2017年2月。在加入布鲁克 BioSpin集团之前,Busse博士于1994年8月至2015年5月期间在飞利浦医疗保健及其子公司担任过各种管理职务,包括2014年1月至2015年5月担任放射解决方案总经理,并于2009年8月至2013年12月担任MR-Therapy总经理。Busse博士拥有Rheinische Friedrich-Wilhelms-Universit t Bonn物理学学士和博士学位。
Falko Busse,has served as President of the Bruker BioSpin Group since May 2018, with responsibility for management of its global operations. Dr. Busse served as Deputy President of the Bruker BioSpin Group from October 2017 until his appointment as President. From March 2017 to September 2017, Dr. Busse served as Executive Vice President of Research and Development, Operations and Marketing at the Bruker BioSpin Group. Dr. Busse joined the Bruker BioSpin Group in June 2015 and served as Executive Vice President of Research and Development until February 2017. Prior to joining the Bruker BioSpin Group, Dr. Busse served in various managerial roles at Philips Healthcare and its subsidiaries from August 1994 until May 2015, including as General Manager Radiology Solutions, from January 2014 to May 2015, and as General Manager MR-Therapy, from August 2009 to December 2013. Dr. Busse holds a B.A. and a Ph.D. in Physics from Rheinische Friedrich-Wilhelms-Universitt Bonn.
Frank H. Laukien

Frank H. Laukien,自1991年2月起,担任本公司的董事长、总裁兼首席执行官;现任布鲁克公司的最大股东。他还担任本公司多间附属公司的董事。自2002年8月至2003年7月布鲁克道尔顿公司和布鲁克AXS公司合并,他担任前上市公司布鲁克AXS公司及其前身公司的执行董事长。此外,从1997年10月至2002年8月,出任董事会主席;从1997年10月至2000年3月,担任布鲁克AXS公司的首席执行官。直至2010年2月,他担任布鲁克BIOSPIN集团的联席首席执行官。弗兰克博士是Joerg C. Laukien(本公司的董事兼布鲁克BIOSPIN公司的执行董事长)的兄弟。弗兰克博士担任生命科学和诊断协会ALDA分析部董事,一个在过去十年被称为分析与生命科学系统协会的行业组织;并从2002年到2003年,担任ALDA董事长。弗兰克博士持有麻省理工学院的学士学位和哈佛大学的化学物理博士学位。 他是MIT科学学院的院长顾问委员会的成员;从2006年到2013年中,担任河流州学校(位于美国马萨诸塞州韦斯顿)的受托人。作为本公司最大的股东,以及他长期领导公司成长的经验,他给董事会带来了具有对公司运营各方面深入了解的一位重要股东的观点。他还提供了在组织管理、战略规划、全球金融和业务发展的丰富行政经验,以及充分理解本公司的关键技术和行业动态的科学技术背景。弗兰克博士现任该公司的最好特别委员会。


Frank H. Laukien,serves as a director of various subsidiaries of Bruker, none of which are publicly traded companies. Dr. Laukien has been elected as a governing trustee of the Dana-Farber Cancer Institute in 2023, and he has been reelected to the ALDA (Analytical, Life-Science & Diagnostics Association) Board in 2021. Dr. Laukien holds a Bachelor of Science degree in physics from MIT, as well as a Ph.D. in chemical physics from Harvard. Dr. Laukien currently serves on the MIT Chemistry Visiting Committee. In 2021, he has been appointed to the Scientific Advisory Boards of the Australian National Phenome Center, and of the Berlin-Brandenburg Innovation Cluster for Cell-based Medicine 'Virchow 2.0'. He is a non-voting board observer in Terrain Biosciences, Inc., an RNA CRO/CDMO startup in which Bruker has a minority investment. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. In 2021, Dr. Laukien was appointed as a Visiting Scholar at Harvard University in the Department of Chemistry and Chemical Biology, and this appointment has been extended for 2024. At Harvard, he participates in the Harvard Origins of Life Initiative and is a co-founder of the Galileo Project at the Center for Astrophysics. In 2021-2023, Dr. Laukien was co-chair of the new scientific working group 'Cancer Evolution' by the American Association of Cancer Research (AACR) Dr. Laukien also is a founding shareholder, angel investor and board member of two New England start-up companies in therapeutics and in space exploration, both outside of Bruker's strategic scope. Dr. Laukien is the author of two scholarly books, called 'Active Biological Evolution' (2022), and 'Origins & Evolution' (2024). Additionally, Dr. Laukien sits on the Boards of Directors of three non-profit entities: FREOPP, a non-partisan think tank that explores ways to expand economic opportunities to disadvantaged people; Heterodox Academy, which promotes viewpoint diversity in Higher Education; and the MIT Free Speech Alliance.
Frank H. Laukien,自1991年2月起,担任本公司的董事长、总裁兼首席执行官;现任布鲁克公司的最大股东。他还担任本公司多间附属公司的董事。自2002年8月至2003年7月布鲁克道尔顿公司和布鲁克AXS公司合并,他担任前上市公司布鲁克AXS公司及其前身公司的执行董事长。此外,从1997年10月至2002年8月,出任董事会主席;从1997年10月至2000年3月,担任布鲁克AXS公司的首席执行官。直至2010年2月,他担任布鲁克BIOSPIN集团的联席首席执行官。弗兰克博士是Joerg C. Laukien(本公司的董事兼布鲁克BIOSPIN公司的执行董事长)的兄弟。弗兰克博士担任生命科学和诊断协会ALDA分析部董事,一个在过去十年被称为分析与生命科学系统协会的行业组织;并从2002年到2003年,担任ALDA董事长。弗兰克博士持有麻省理工学院的学士学位和哈佛大学的化学物理博士学位。 他是MIT科学学院的院长顾问委员会的成员;从2006年到2013年中,担任河流州学校(位于美国马萨诸塞州韦斯顿)的受托人。作为本公司最大的股东,以及他长期领导公司成长的经验,他给董事会带来了具有对公司运营各方面深入了解的一位重要股东的观点。他还提供了在组织管理、战略规划、全球金融和业务发展的丰富行政经验,以及充分理解本公司的关键技术和行业动态的科学技术背景。弗兰克博士现任该公司的最好特别委员会。
Frank H. Laukien,serves as a director of various subsidiaries of Bruker, none of which are publicly traded companies. Dr. Laukien has been elected as a governing trustee of the Dana-Farber Cancer Institute in 2023, and he has been reelected to the ALDA (Analytical, Life-Science & Diagnostics Association) Board in 2021. Dr. Laukien holds a Bachelor of Science degree in physics from MIT, as well as a Ph.D. in chemical physics from Harvard. Dr. Laukien currently serves on the MIT Chemistry Visiting Committee. In 2021, he has been appointed to the Scientific Advisory Boards of the Australian National Phenome Center, and of the Berlin-Brandenburg Innovation Cluster for Cell-based Medicine 'Virchow 2.0'. He is a non-voting board observer in Terrain Biosciences, Inc., an RNA CRO/CDMO startup in which Bruker has a minority investment. In May 2017, Dr. Laukien was elected a senator of acatech, the German National Academy of Science and Engineering. In 2021, Dr. Laukien was appointed as a Visiting Scholar at Harvard University in the Department of Chemistry and Chemical Biology, and this appointment has been extended for 2024. At Harvard, he participates in the Harvard Origins of Life Initiative and is a co-founder of the Galileo Project at the Center for Astrophysics. In 2021-2023, Dr. Laukien was co-chair of the new scientific working group 'Cancer Evolution' by the American Association of Cancer Research (AACR) Dr. Laukien also is a founding shareholder, angel investor and board member of two New England start-up companies in therapeutics and in space exploration, both outside of Bruker's strategic scope. Dr. Laukien is the author of two scholarly books, called 'Active Biological Evolution' (2022), and 'Origins & Evolution' (2024). Additionally, Dr. Laukien sits on the Boards of Directors of three non-profit entities: FREOPP, a non-partisan think tank that explores ways to expand economic opportunities to disadvantaged people; Heterodox Academy, which promotes viewpoint diversity in Higher Education; and the MIT Free Speech Alliance.
Burkhard Prause

Burkhard Prause哲学博士自2008年4月以来担任总裁兼首席执行官。他还担任Bruker EAS和Bruker HTS(自2005年1月以来),RI Research Instruments GmbH(自2008年12月以来)和Bruker ASC GmbH(自2009年3月以来)的总经理。在此之前,他担任Bruker BioSpin MRI GmbH的产品经理。他于2002年加入Bruker BioSpin MRI GmbH。他是德国图宾根the Max-Planck Institute的高级研究员。他目前担任CCAS(the Coalition for the Commercial Application of Superconductors)的董事,从2006年到2010年担任ivSupra(德国超导产业联盟)的副主席。他持有the University of Notre Dame的物理学博士学位。


Burkhard Prause has served as President and Chief Executive Officer since April 2008. He has also served as a Managing Director of Bruker EAS and Bruker HTS since January 2005 RI Research Instruments GmbH since December 2008 and Bruker ASC GmbH since March 2009. Prior to that time, Dr. Prause served as Product Manr for Bruker BioSpin MRI GmbH. Before joining Bruker BioSpin MRI GmbH in 2002 Dr. Prause was a senior staff scientist at the Max-Planck Institute in Tubingen, Germany. Dr. Prause currently serves as a director of CCAS the Coalition for the Commercial Application of Superconductors, and from 2006 to 2010 Dr. Prause served as Vice Chairman of ivSupra, a German superconductor industry coalition. Dr. Prause holds a Ph.D. in physics from the University of Notre Dame.
Burkhard Prause哲学博士自2008年4月以来担任总裁兼首席执行官。他还担任Bruker EAS和Bruker HTS(自2005年1月以来),RI Research Instruments GmbH(自2008年12月以来)和Bruker ASC GmbH(自2009年3月以来)的总经理。在此之前,他担任Bruker BioSpin MRI GmbH的产品经理。他于2002年加入Bruker BioSpin MRI GmbH。他是德国图宾根the Max-Planck Institute的高级研究员。他目前担任CCAS(the Coalition for the Commercial Application of Superconductors)的董事,从2006年到2010年担任ivSupra(德国超导产业联盟)的副主席。他持有the University of Notre Dame的物理学博士学位。
Burkhard Prause has served as President and Chief Executive Officer since April 2008. He has also served as a Managing Director of Bruker EAS and Bruker HTS since January 2005 RI Research Instruments GmbH since December 2008 and Bruker ASC GmbH since March 2009. Prior to that time, Dr. Prause served as Product Manr for Bruker BioSpin MRI GmbH. Before joining Bruker BioSpin MRI GmbH in 2002 Dr. Prause was a senior staff scientist at the Max-Planck Institute in Tubingen, Germany. Dr. Prause currently serves as a director of CCAS the Coalition for the Commercial Application of Superconductors, and from 2006 to 2010 Dr. Prause served as Vice Chairman of ivSupra, a German superconductor industry coalition. Dr. Prause holds a Ph.D. in physics from the University of Notre Dame.
Mark R. Munch

Mark R. Munch,自2012年9月起,担任布鲁克MAT集团的总裁,负责管理布鲁克MAT集团的全球业务,该集团制造和分销公司先进的X射线分析技术和火花发射光谱、原子力显微镜和手写笔和光学计量仪器(用于非破坏性分子、材料和元素分析)。自2010年10月起,蒙克博士还担任布鲁克纳米公司的总裁,一家本公司的全资附属公司。在加盟布鲁克纳米公司之前,从2008年2月至2010年10月,蒙克博士担任威科仪器公司的执行副总裁。从2006年2月至2008年1月,蒙克博士担任Coherent公司的高级副总裁;从2004年至2006年,担任Cooligy公司的总裁兼首席执行官,一家艾默生电气公司的附属公司。蒙克博士的背景包括超过23年的市场营销、产品开发、运营和销售经验,以及在管理跨国公司的重要业务部门的经验。蒙克博士拥有科罗拉多大学的化学工程学士学位、斯坦福大学的科学硕士学位和化学工程博士学位。


Mark R. Munch,has served since September 2012 as President, Bruker NANO Group, with responsibility for management of its global operations. He has also served, since July 2015, as an Executive Vice President of Bruker, and in that capacity is responsible for providing oversight to Bruker Corporation global information technology function and enterprise resource planning, as well as other strategic management development and business process initiatives. Dr. Munch has also served as President of Bruker NANO, Inc., a wholly owned subsidiary of Bruker, since October 2010. In March 2021, Dr. Munch took on an additional role of Chief Executive Officer of Bruker Spatial Genomics, a Bruker majority investment. Prior to joining Bruker NANO, Inc., from February 2008 to October 2010, Dr. Munch was Executive Vice President of Veeco Instruments Inc. Dr. Munch also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006. Dr. Munch's background includes over 29 years of experience in marketing, product development, operations and sales, as well as experience in managing significant business units of multi-national corporations. Dr. Munch holds a Bachelor of Science degree in Chemical Engineering from the University of Colorado and a Master of Science degree and a Ph.D. in Chemical Engineering from Stanford University.
Mark R. Munch,自2012年9月起,担任布鲁克MAT集团的总裁,负责管理布鲁克MAT集团的全球业务,该集团制造和分销公司先进的X射线分析技术和火花发射光谱、原子力显微镜和手写笔和光学计量仪器(用于非破坏性分子、材料和元素分析)。自2010年10月起,蒙克博士还担任布鲁克纳米公司的总裁,一家本公司的全资附属公司。在加盟布鲁克纳米公司之前,从2008年2月至2010年10月,蒙克博士担任威科仪器公司的执行副总裁。从2006年2月至2008年1月,蒙克博士担任Coherent公司的高级副总裁;从2004年至2006年,担任Cooligy公司的总裁兼首席执行官,一家艾默生电气公司的附属公司。蒙克博士的背景包括超过23年的市场营销、产品开发、运营和销售经验,以及在管理跨国公司的重要业务部门的经验。蒙克博士拥有科罗拉多大学的化学工程学士学位、斯坦福大学的科学硕士学位和化学工程博士学位。
Mark R. Munch,has served since September 2012 as President, Bruker NANO Group, with responsibility for management of its global operations. He has also served, since July 2015, as an Executive Vice President of Bruker, and in that capacity is responsible for providing oversight to Bruker Corporation global information technology function and enterprise resource planning, as well as other strategic management development and business process initiatives. Dr. Munch has also served as President of Bruker NANO, Inc., a wholly owned subsidiary of Bruker, since October 2010. In March 2021, Dr. Munch took on an additional role of Chief Executive Officer of Bruker Spatial Genomics, a Bruker majority investment. Prior to joining Bruker NANO, Inc., from February 2008 to October 2010, Dr. Munch was Executive Vice President of Veeco Instruments Inc. Dr. Munch also served as a Senior Vice President of Coherent, Inc. from February 2006 to January 2008 and as President and Chief Executive Officer of Cooligy, Inc., a subsidiary of Emerson Electric, from 2004 to 2006. Dr. Munch's background includes over 29 years of experience in marketing, product development, operations and sales, as well as experience in managing significant business units of multi-national corporations. Dr. Munch holds a Bachelor of Science degree in Chemical Engineering from the University of Colorado and a Master of Science degree and a Ph.D. in Chemical Engineering from Stanford University.
Juergen Srega

Juergen Srega ,2013年1月,加入本公司担任布鲁克CALID集团总裁。任职期间,他负责布管理鲁克CALID集团的整体营运,该集团生产和销售本公司用于生命科学和应用市场的质谱和色谱仪器,以及用于化学、生物、放射性、核和爆炸物探测和研究的分析仪器,和基于红外和拉曼分子光谱技术的过程仪表分析仪器。 他还担任布鲁克道尔顿公司的总经理,本公司位于德国的一间全资拥有的附属公司。在加入本公司之前,自1996年以来,他在赛默飞世尔科技公司担任各种高级管理职位,一家总部位于马萨诸塞州沃尔瑟姆的为研究、分析、发现和诊断提供分析仪器、设备、试剂和耗材、软件和服务的全球供应商。在赛默飞世尔科技公司,他率领多个重要运营部门,包括:2011年至2012年,担任勃拉姆斯有限公司的副总裁和总经理;2005年至2011年,担任全球产品科学仪器事业部副总裁兼总经理;1996年至2004年,担任先进MS副总裁和总经理。在1996年之前,1988年至1995年,他任职于Badenwerk 公司,一家德国的电力公用事业公司(位于德国卡尔斯鲁厄);1980年至1988年,担任布鲁克有限公司的职员。他持有德国汉堡北部学院的金融学士学位和卡尔斯鲁厄应用科技大学(位于德国卡尔斯鲁厄)的工程学士学位。


Juergen Srega has served as President of the Bruker CALID Group since January 2013 with responsibility for management of the global operations of Bruker Corporation's Bruker CALID Group, which manufactures and distributes the Company's mass spectrometry and chromatography instruments for life science and applied markets, as well as analytical instruments for chemical, biological, radiological, nuclear and explosives detection and research and process instruments based on infrared and Raman molecular spectroscopy technologies. Mr. Srega also serves as a Managing Director of Bruker Daltonik GmbH, an indirect wholly-owned subsidiary of the Company located in Germany. Prior to joining the Company, Mr. Srega served since 1996 in a variety of senior management roles at Thermo Fisher Scientific Inc., a global provider of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics headquartered in Waltham, Massachusetts. At Thermo Fisher Scientific, Mr. Srega led a number of significant operating divisions, including as Vice President and General Manager Biomarkers, BRAHMS GmbH, from 2011 to 2012 Vice President and General Manager Scientific Instruments Division Global Products from 2005 to 2011 and Vice President and General Manager Advanced MS from 1996 to 2004. Prior to 1996 Mr. Srega was with Badenwerk AG, a German power utility company located in Karlsruhe, Germany, from 1988 to 1995 and an employee of Bruker GmbH from 1980 to 1988. Mr. Srega holds a B.A. in Finance from Nord Akademie in Hamburg, Germany and a B.A. in Engineering from Karlsruhe University of Applied Science in Karlsruhe, Germany.
Juergen Srega ,2013年1月,加入本公司担任布鲁克CALID集团总裁。任职期间,他负责布管理鲁克CALID集团的整体营运,该集团生产和销售本公司用于生命科学和应用市场的质谱和色谱仪器,以及用于化学、生物、放射性、核和爆炸物探测和研究的分析仪器,和基于红外和拉曼分子光谱技术的过程仪表分析仪器。 他还担任布鲁克道尔顿公司的总经理,本公司位于德国的一间全资拥有的附属公司。在加入本公司之前,自1996年以来,他在赛默飞世尔科技公司担任各种高级管理职位,一家总部位于马萨诸塞州沃尔瑟姆的为研究、分析、发现和诊断提供分析仪器、设备、试剂和耗材、软件和服务的全球供应商。在赛默飞世尔科技公司,他率领多个重要运营部门,包括:2011年至2012年,担任勃拉姆斯有限公司的副总裁和总经理;2005年至2011年,担任全球产品科学仪器事业部副总裁兼总经理;1996年至2004年,担任先进MS副总裁和总经理。在1996年之前,1988年至1995年,他任职于Badenwerk 公司,一家德国的电力公用事业公司(位于德国卡尔斯鲁厄);1980年至1988年,担任布鲁克有限公司的职员。他持有德国汉堡北部学院的金融学士学位和卡尔斯鲁厄应用科技大学(位于德国卡尔斯鲁厄)的工程学士学位。
Juergen Srega has served as President of the Bruker CALID Group since January 2013 with responsibility for management of the global operations of Bruker Corporation's Bruker CALID Group, which manufactures and distributes the Company's mass spectrometry and chromatography instruments for life science and applied markets, as well as analytical instruments for chemical, biological, radiological, nuclear and explosives detection and research and process instruments based on infrared and Raman molecular spectroscopy technologies. Mr. Srega also serves as a Managing Director of Bruker Daltonik GmbH, an indirect wholly-owned subsidiary of the Company located in Germany. Prior to joining the Company, Mr. Srega served since 1996 in a variety of senior management roles at Thermo Fisher Scientific Inc., a global provider of analytical instruments, equipment, reagents and consumables, software and services for research, analysis, discovery and diagnostics headquartered in Waltham, Massachusetts. At Thermo Fisher Scientific, Mr. Srega led a number of significant operating divisions, including as Vice President and General Manager Biomarkers, BRAHMS GmbH, from 2011 to 2012 Vice President and General Manager Scientific Instruments Division Global Products from 2005 to 2011 and Vice President and General Manager Advanced MS from 1996 to 2004. Prior to 1996 Mr. Srega was with Badenwerk AG, a German power utility company located in Karlsruhe, Germany, from 1988 to 1995 and an employee of Bruker GmbH from 1980 to 1988. Mr. Srega holds a B.A. in Finance from Nord Akademie in Hamburg, Germany and a B.A. in Engineering from Karlsruhe University of Applied Science in Karlsruhe, Germany.